Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 34, 304-307, February 1, 1974]
© 1974 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedlaender, G. E.
Right arrow Articles by Mitchell, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedlaender, G. E.
Right arrow Articles by Mitchell, M. S.

Effect of 2,7-Bis[2-diethylamino)ethoxy]fluoren-9-one dihydrochloride (Tilorone) upon Cell-mediated Immunity in Mice1

Gary E. Friedlaender2, Michael B. Mosher3 and Malcolm S. Mitchell4

Departments of Medicine and Pharmacology and Section of Orthopedic Surgery, Yale University School of Medicine, New Haven, Connecticut 06510

Tilorone (2,7-bis[2-(diethylamino)ethoxy]fluoren-9-one dihydrochloride) was administered to CD-1 or C57L x A F1 mice alone or with allogeneic leukemia L1210 cells. Tilorone given alone elicited thymus-dependent lymphocytes in the spleen causing cell-mediated immunity (CMI) comparable to that of lymphocytes exposed to 5 x 104 L1210 cells. This occurred whether Tilorone was administered p.o. or i.p. When administered 24 hr after L1210 cells, an adjuvant effect of Tilorone upon CMI was not demonstrable unless glass-adherent spleen cells were removed before in vitro assay. In groups given Tilorone or L1210 alone, CMI was unchanged after removal of adherent cells. Release of lymphoycte-activating factor by the spleen was unaffected by Tilorone. It is suggested that Tilorone has a moderate direct stimulatory effect upon thymus-dependent lymphocytes but may elicit inhibitory effects mediated by adherent spleen cells (macrophages and/or sticky bursa-dependent lymphocytes) that have also been stimulated by antigen.

1 Supported by American Cancer Society Grant IC-72 and USPHS Grant CA 13105.

2 Instructor in Surgery. Formerly a postdoctoral fellow in Orthopedic Surgery under USPHS Grant AM 05416.

3 Formerly Trainee in Clinical Pharmacology and Chemotherapy under USPHS Grant CA 05318.

4 Leukemia Society Scholar; to whom requests for reprints should be addressed, at 333 Cedar Street, New Haven, Conn. 06510.

Received 8/15/73. Accepted 10/31/73.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1974 by the American Association for Cancer Research.